Literature DB >> 20478874

Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Daniel J Foti1, Roman Kotov, Lin T Guey, Evelyn J Bromet.   

Abstract

OBJECTIVE: The authors examined the relationship between cannabis use and the course of illness in schizophrenia over 10 years of follow-up after first psychiatric hospitalization.
METHOD: The authors assessed 229 patients with a schizophrenia spectrum disorder five times: during the first admission and 6 months, 2 years, 4 years, and 10 years later. Ratings of cannabis use and psychiatric symptoms (psychotic, negative, disorganized, and depressive) were made at each assessment.
RESULTS: The lifetime rate of cannabis use was 66.2%, and survival analysis revealed that lifetime use was associated with an earlier onset of psychosis. The rates of current use ranged from 10% to 18% across assessments. Cannabis status was moderately stable, with tetrachoric correlation coefficients between waves ranging from 0.48 to 0.78. Mixed-effects logistic regression revealed that changes in cannabis use were associated with changes in psychotic symptoms over time even after gender, age, socioeconomic status, other drug use, antipsychotic medication use, and other symptoms were controlled for. Structural equation modeling indicated that the association with psychotic symptoms was bidirectional.
CONCLUSIONS: Cannabis use is associated with an adverse course of psychotic symptoms in schizophrenia, and vice versa, even after taking into account other clinical, substance use, and demographic variables.

Entities:  

Mesh:

Year:  2010        PMID: 20478874      PMCID: PMC3594105          DOI: 10.1176/appi.ajp.2010.09020189

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  33 in total

1.  [Relevance of drug use in clinical manifestations of schizophrenia].

Authors:  F Arias Horcajadas; S Sánchez Romero; J J Padín Calo
Journal:  Actas Esp Psiquiatr       Date:  2002 Mar-Apr       Impact factor: 1.196

2.  Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis.

Authors:  J E Schwartz; S Fennig; M Tanenberg-Karant; G Carlson; T Craig; N Galambos; J Lavelle; E J Bromet
Journal:  Arch Gen Psychiatry       Date:  2000-06

3.  Testing hypotheses about the relationship between cannabis use and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall; Michael Lynskey
Journal:  Drug Alcohol Depend       Date:  2003-07-20       Impact factor: 4.492

4.  Meta-analysis of symptom factors in schizophrenia.

Authors:  B S Grube; R M Bilder; R S Goldman
Journal:  Schizophr Res       Date:  1998-05-25       Impact factor: 4.939

Review 5.  Treatments for patients with dual diagnosis: a review.

Authors:  Quyen Q Tiet; Brent Mausbach
Journal:  Alcohol Clin Exp Res       Date:  2007-04       Impact factor: 3.455

6.  Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study.

Authors:  L Hides; S Dawe; D J Kavanagh; R McD Young
Journal:  Br J Psychiatry       Date:  2006-08       Impact factor: 9.319

7.  Cannabis use and the risk of developing a psychotic disorder.

Authors:  Wayne Hall; Louisa Degenhardt
Journal:  World Psychiatry       Date:  2008       Impact factor: 49.548

8.  The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.

Authors:  Louisa Degenhardt; Chris Tennant; Stuart Gilmour; David Schofield; Louise Nash; Wayne Hall; Diana McKay
Journal:  Psychol Med       Date:  2007-02-09       Impact factor: 7.723

Review 9.  The effect of cannabis on the brain: can it cause brain anomalies that lead to increased risk for schizophrenia?

Authors:  Lynn E DeLisi
Journal:  Curr Opin Psychiatry       Date:  2008-03       Impact factor: 4.741

Review 10.  Effects of cannabis use on outcomes of psychotic disorders: systematic review.

Authors:  Stanley Zammit; Theresa H M Moore; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Br J Psychiatry       Date:  2008-11       Impact factor: 9.319

View more
  58 in total

1.  Association of abnormal semantic processing with delusion-like ideation in frequent cannabis users: an electrophysiological study.

Authors:  Michael Kiang; Bruce K Christensen; David L Streiner; Carolyn Roy; Iulia Patriciu; Robert B Zipursky
Journal:  Psychopharmacology (Berl)       Date:  2012-07-11       Impact factor: 4.530

Review 2.  Blurred boundaries: the therapeutics and politics of medical marijuana.

Authors:  J Michael Bostwick
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

3.  Medical marijuana use and suicide attempt in a patient with major depressive disorder.

Authors:  Abraham Nussbaum; Christian Thurstone; Ingrid Binswanger
Journal:  Am J Psychiatry       Date:  2011-08       Impact factor: 18.112

4.  Genetic predisposition to schizophrenia associated with increased use of cannabis.

Authors:  R A Power; K J H Verweij; M Zuhair; G W Montgomery; A K Henders; A C Heath; P A F Madden; S E Medland; N R Wray; N G Martin
Journal:  Mol Psychiatry       Date:  2014-06-24       Impact factor: 15.992

5.  The lifetime and past-year prevalence of dual diagnosis in people with schizophrenia across Europe: findings from the European Schizophrenia Cohort (EuroSC).

Authors:  Giuseppe Carrà; Sonia Johnson; Paul Bebbington; Matthias C Angermeyer; Dirk Heider; Traolach Brugha; Jean-Michel Azorin; Mondher Toumi
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-03-17       Impact factor: 5.270

6.  Clearing the smoke: what do we know about adolescent cannabis use and schizophrenia?

Authors:  Matthew N Hill
Journal:  J Psychiatry Neurosci       Date:  2014-03       Impact factor: 6.186

7.  Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder.

Authors:  Glenn T Konopaske; Nicholas Lange; Joseph T Coyle; Francine M Benes
Journal:  JAMA Psychiatry       Date:  2014-12-01       Impact factor: 21.596

8.  Acute administration of Δ⁹ tetrahydrocannabinol does not prevent enhancement of sensory gating by clozapine in DBA/2 mice.

Authors:  Jason Smucny; Karen E Stevens; Jason R Tregellas
Journal:  Pharmacol Biochem Behav       Date:  2014-01-10       Impact factor: 3.533

9.  A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010.

Authors:  Stephen S Lim; Theo Vos; Abraham D Flaxman; Goodarz Danaei; Kenji Shibuya; Heather Adair-Rohani; Markus Amann; H Ross Anderson; Kathryn G Andrews; Martin Aryee; Charles Atkinson; Loraine J Bacchus; Adil N Bahalim; Kalpana Balakrishnan; John Balmes; Suzanne Barker-Collo; Amanda Baxter; Michelle L Bell; Jed D Blore; Fiona Blyth; Carissa Bonner; Guilherme Borges; Rupert Bourne; Michel Boussinesq; Michael Brauer; Peter Brooks; Nigel G Bruce; Bert Brunekreef; Claire Bryan-Hancock; Chiara Bucello; Rachelle Buchbinder; Fiona Bull; Richard T Burnett; Tim E Byers; Bianca Calabria; Jonathan Carapetis; Emily Carnahan; Zoe Chafe; Fiona Charlson; Honglei Chen; Jian Shen Chen; Andrew Tai-Ann Cheng; Jennifer Christine Child; Aaron Cohen; K Ellicott Colson; Benjamin C Cowie; Sarah Darby; Susan Darling; Adrian Davis; Louisa Degenhardt; Frank Dentener; Don C Des Jarlais; Karen Devries; Mukesh Dherani; Eric L Ding; E Ray Dorsey; Tim Driscoll; Karen Edmond; Suad Eltahir Ali; Rebecca E Engell; Patricia J Erwin; Saman Fahimi; Gail Falder; Farshad Farzadfar; Alize Ferrari; Mariel M Finucane; Seth Flaxman; Francis Gerry R Fowkes; Greg Freedman; Michael K Freeman; Emmanuela Gakidou; Santu Ghosh; Edward Giovannucci; Gerhard Gmel; Kathryn Graham; Rebecca Grainger; Bridget Grant; David Gunnell; Hialy R Gutierrez; Wayne Hall; Hans W Hoek; Anthony Hogan; H Dean Hosgood; Damian Hoy; Howard Hu; Bryan J Hubbell; Sally J Hutchings; Sydney E Ibeanusi; Gemma L Jacklyn; Rashmi Jasrasaria; Jost B Jonas; Haidong Kan; John A Kanis; Nicholas Kassebaum; Norito Kawakami; Young-Ho Khang; Shahab Khatibzadeh; Jon-Paul Khoo; Cindy Kok; Francine Laden; Ratilal Lalloo; Qing Lan; Tim Lathlean; Janet L Leasher; James Leigh; Yang Li; John Kent Lin; Steven E Lipshultz; Stephanie London; Rafael Lozano; Yuan Lu; Joelle Mak; Reza Malekzadeh; Leslie Mallinger; Wagner Marcenes; Lyn March; Robin Marks; Randall Martin; Paul McGale; John McGrath; Sumi Mehta; George A Mensah; Tony R Merriman; Renata Micha; Catherine Michaud; Vinod Mishra; Khayriyyah Mohd Hanafiah; Ali A Mokdad; Lidia Morawska; Dariush Mozaffarian; Tasha Murphy; Mohsen Naghavi; Bruce Neal; Paul K Nelson; Joan Miquel Nolla; Rosana Norman; Casey Olives; Saad B Omer; Jessica Orchard; Richard Osborne; Bart Ostro; Andrew Page; Kiran D Pandey; Charles D H Parry; Erin Passmore; Jayadeep Patra; Neil Pearce; Pamela M Pelizzari; Max Petzold; Michael R Phillips; Dan Pope; C Arden Pope; John Powles; Mayuree Rao; Homie Razavi; Eva A Rehfuess; Jürgen T Rehm; Beate Ritz; Frederick P Rivara; Thomas Roberts; Carolyn Robinson; Jose A Rodriguez-Portales; Isabelle Romieu; Robin Room; Lisa C Rosenfeld; Ananya Roy; Lesley Rushton; Joshua A Salomon; Uchechukwu Sampson; Lidia Sanchez-Riera; Ella Sanman; Amir Sapkota; Soraya Seedat; Peilin Shi; Kevin Shield; Rupak Shivakoti; Gitanjali M Singh; David A Sleet; Emma Smith; Kirk R Smith; Nicolas J C Stapelberg; Kyle Steenland; Heidi Stöckl; Lars Jacob Stovner; Kurt Straif; Lahn Straney; George D Thurston; Jimmy H Tran; Rita Van Dingenen; Aaron van Donkelaar; J Lennert Veerman; Lakshmi Vijayakumar; Robert Weintraub; Myrna M Weissman; Richard A White; Harvey Whiteford; Steven T Wiersma; James D Wilkinson; Hywel C Williams; Warwick Williams; Nicholas Wilson; Anthony D Woolf; Paul Yip; Jan M Zielinski; Alan D Lopez; Christopher J L Murray; Majid Ezzati; Mohammad A AlMazroa; Ziad A Memish
Journal:  Lancet       Date:  2012-12-15       Impact factor: 79.321

10.  Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed.

Authors:  Margaret Haney; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2015-08-19       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.